Bone density during rapid weight loss: what is known, which is less than you would hope
The evidence base is one secondary analysis, several small studies and a large amount of extrapolation from bariatric surgery.
February 2026
Everything filed in February 2026, the month of Volume 3, Number 2. The issue itself — cover, editor’s letter and table of contents — is here.
VendorInvestigate result on a Shanghai tirzepatide lot lands 1.3 points below the supplier’s figure
The result is unremarkable. What the report omits is not.
What changed at TFC in February, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
A shortage listing ends. 3 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
The half-life question, answered properly
Half-life, accumulation ratio and time to steady state are three separate quantities, and confusing them produces most of the bad advice in circulation.
What happens in solution that does not happen in the cake
We set out what is known, what is inferred and what is simply assumed about the fortnight after a vial is opened.
Japan declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Xi'an export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
The 27-day notice: how a compounding wind-down works in the United Arab Emirates
The document is four pages. Three of them are about dates.
Halvard & Pike Apothecary of Portland, Maine closes after 5 years
A proper account of an operation that existed, and of what closing it cost.
Sterility is not a percentage, which is the whole difficulty
Purity, content, identity, sterility and endotoxin are five separate determinations. A single sheet of paper carrying one of them is not evidence about the other four.
Why SSA can be entirely straightforward and still tell you nothing about bioburden
The Journal has read several hundred certificates from twenty companies. We set out what the documents actually cover, and what a reader is filling in from imagination.
Dose-limiting: a definition worth being strict about
Trial discontinuation figures are a floor, not an estimate: trial populations are supported in ways ordinary patients are not.
Independent analysis puts a QSC survodutide lot at 99.4%, against 95.9% on the certificate
The report states the gradient, the wavelength and the integration threshold, which is more than most.
STEP 2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A supplier suspends shipping to India after 17 consecutive customs detentions
The route did not close because of a rule about peptides.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
A guide to the results that will resolve themselves
A substantial proportion of the abnormal results generated during rapid weight loss are consequences of the weight loss rather than findings about the person.
Chain of custody, and where it begins
Chain of custody, in a regulated setting, begins at sampling. Here it begins when the package arrives.
Medutest result on a Wuhan dulaglutide lot lands 0.7 points below the supplier’s figure
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.
What changed at FGP in February, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The 6-day notice: how a compounding wind-down works in South Africa
The document is four pages. Three of them are about dates.
Inspectors cite the consolidator trading as Meridian Freight Partners over sterility assurance
The observation that closes a facility is rarely the dramatic one.
How a claim degrades between the bench and the listing
A badge asserts that something was tested. It does not assert what, when, on whose sample, by what method, or whether the lot on sale is the lot that was tested.
An interlaboratory comparison nobody had run
The Journal submitted split samples from single lots to three assay services, under names unconnected to this publication, and published each method alongside each result.
Ireland declines to reimburse liraglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
WWB declines, for the 15th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Poland pharmacy body issues counselling standards for tirzepatide initiation
The evidence base is thin and the document says so, which is to its credit.
The quiet end of the consolidator trading as Meridian Freight Partners
A proper account of an operation that existed, and of what closing it cost.
Janoshik, Medutest, PeptideMeter, VendorInvestigate: a capability audit
The absence of microbiological capability in this market is a commercial fact with a straightforward explanation, and it is worth understanding before blaming anybody for it.
Why "muscle-sparing" is a marketing term and not a measurement
Almost every practical recommendation in circulation was established in a population that does not resemble the people now following it.
GGPeps declines, for the 22nd time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Germany health authority warns on falsified tirzepatide pens
Reported from the analysis, not from a warning notice.
From the floor in Chengdu: 21 posters, one theme
Reported from the sessions, and from the two hours afterwards.
What the new France guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What STEP 4 and SURMOUNT-4 actually established
A plateau at an intermediate dose and a plateau at the maximum dose look identical from the outside and mean different things.
Accreditation, scope, and the question nobody asks VendorInvestigate
Two signatures — one who performed the work, one who approved its release — are the ordinary regulated convention and are almost unknown here.
The limits of mechanism: why receptor data will not tell you who responds
Receptor pharmacology is strong on average effects and almost silent on individual variation. That gap is where most reader questions live.
STEP 8 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.